North America dominates the global market for blood-brain barrier technologies given the rising incidence of neurological diseases and growing geriatric population in the region. Asia is expected to show high growth rates in the next five years in the global blood-brain barrier technologies market, with China and India being the fastest growing markets in Asia Pacific. The key driving forces for the blood-brain barrier technologies market in developing countries are the large pool of patients, increasing awareness about the disease, improving healthcare infrastructure, and rising government funding in the region.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/4183
Increasing prevalence of neurological diseases such as meningitis, multiple sclerosis, Parkinson’s disease, and encephalitis, growing geriatric population, increasing in healthcare expenditure, rising investment in research and development for the development of new drugs and delivery devices, increasing awareness about healthcare, and increasing number of initiatives by various governments and government associations are some of the key factors driving the growth of the global blood-brain barrier technologies market. However, complex regulatory frameworks for the approval of drugs in most countries and long approval time for drugs owing to the insufficient knowledge of the brain are major restraints for the growth of the global blood-brain barrier technologies market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/4183
Innovation of drugs and delivery devices to cross the blood-brain barrier would help develop opportunities for the global blood-brain barrier technologies market. The major companies operating in the global blood-brain barrier technologies market are Teva Pharmaceuticals Industries, Ltd., F. Hoffmann La-Roche, Ltd., Eli Lilly and Company, Fabre-Kramer Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., biOasia Technologies, Inc., Cypress Biosciences, Inc., Janssen Pharmaceutical N.V., NeuroVive Pharmaceutical AB, and ArmaGen.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353